MERRIMACK PHARMACEUTICALS IN's ticker is MACK and the CUSIP is 590328209. A total of 41 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $486,935 | +501.2% | 42,490 | +97.5% | 0.00% | – |
| Q3 2022 | $81,000 | -45.3% | 21,519 | -13.6% | 0.00% | – |
| Q2 2022 | $148,000 | -23.7% | 24,919 | -18.9% | 0.00% | -100.0% |
| Q1 2022 | $194,000 | +37.6% | 30,739 | -14.5% | 0.00% | – |
| Q4 2021 | $141,000 | -36.5% | 35,966 | -21.7% | 0.00% | – |
| Q3 2021 | $222,000 | -44.1% | 45,915 | -26.1% | 0.00% | -100.0% |
| Q2 2021 | $397,000 | -70.9% | 62,119 | -71.4% | 0.00% | -75.0% |
| Q1 2021 | $1,362,000 | -26.1% | 216,841 | -19.0% | 0.00% | -20.0% |
| Q4 2020 | $1,843,000 | +3023.7% | 267,555 | +1329.7% | 0.01% | – |
| Q4 2019 | $59,000 | -41.0% | 18,714 | -16.1% | 0.00% | – |
| Q3 2019 | $100,000 | -28.1% | 22,314 | -3.0% | 0.00% | – |
| Q2 2019 | $139,000 | -59.6% | 23,014 | -53.5% | 0.00% | -100.0% |
| Q1 2019 | $344,000 | +22.4% | 49,483 | -32.1% | 0.00% | 0.0% |
| Q4 2018 | $281,000 | -7.0% | 72,877 | +28.7% | 0.00% | 0.0% |
| Q3 2018 | $302,000 | – | 56,623 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Western Standard LLC | 1,894,013 | $23,353,180 | 21.09% |
| Newtyn Management, LLC | 1,873,694 | $23,102,647 | 5.70% |
| Sio Capital Management, LLC | 288,466 | $3,556,786 | 1.10% |
| Madison Avenue Partners, LP | 553,085 | $6,819,538 | 0.97% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 209,739 | $2,586 | 0.95% |
| Indaba Capital Management, L.P. | 136,802 | $1,686,769 | 0.50% |
| Sepio Capital, LP | 306,680 | $3,781,364 | 0.33% |
| Yakira Capital Management, Inc. | 54,118 | $667,275 | 0.18% |
| Centiva Capital, LP | 187,803 | $2,315,611 | 0.05% |
| FIFTH LANE CAPITAL, LP | 10,929 | $134,427 | 0.05% |